San Francisco's Renovis Inc. completed a second round of venture financing on Jan. 9. The round brought in more than $34 million for the company.
The lead investor was HBM BioVentures AG. Other investors included Applied Genomic Technology Capital Funds, Bioveda Capital and DeNovo Ventures.
Renovis produces and sells drugs th...
The lead investor was HBM BioVentures AG. Other investors included Applied Genomic Technology Capital Funds, Bioveda Capital and DeNovo Ventures.
Renovis produces and sells drugs th...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In